Administration of 17β-estradiol to ovariectomized obese female mice reverses obesity-hypertension through an ACE2-dependent mechanism

American Journal of Physiology - Endocrinology and Metabolism

Volumn 308, Issue 12, 2015, Pages E1066-E1075

  Wang, Yu ^a   Shoemaker, Robin ^a   Thatcher, Sean E ^a   Batifoulier Yiannikouris, Frederique ^a   English, Victoria L ^a   Cassis, Lisa A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

17 estradiol; Blood pressure; Ovariectomy; Renin angiotensin system

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; DIPEPTIDYL CARBOXYPEPTIDASE;

3T3 CELL LINE; ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET INDUCED OBESITY; DOSE RESPONSE; ESTRADIOL BLOOD LEVEL; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENOTYPE; HEART RATE; HEART WEIGHT; HYPERTENSION; IN VITRO STUDY; LIGHT DARK CYCLE; LIPID DIET; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OVARIECTOMY; PHYSICAL ACTIVITY; PILOT STUDY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; SYSTOLIC BLOOD PRESSURE; UTERUS WEIGHT; ANIMAL; BLOOD PRESSURE; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; GENETICS; METABOLISM; MOUSE MUTANT; OBESITY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ADIPOCYTES; ADIPOSITY; ANIMALS; BLOOD PRESSURE; ESTRADIOL; FEMALE; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MICE, TRANSGENIC; OBESITY; OVARIECTOMY; PEPTIDYL-DIPEPTIDASE A; SIGNAL TRANSDUCTION;

EID: 84931075374     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00030.2015     Document Type: Article

References (42)

1. Bharadwaj MS, Strawn WB, Groban L, Yamaleyeva LM, Chappell MC, Horta C, Atkins K, Firmes L, Gurley SB, Brosnihan KB. Angiotensin-converting enzyme 2 deficiency is associated with impaired gestational weight gain and fetal growth restriction. Hypertension 58: 852–858, 2011.
2. Boustany CM, Bharadwaj K, Daugherty A, Brown DR, Randall DC, Cassis LA. Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp Physiol 287: R943–R949, 2004.
3. Cacciatore B, Paakkari I, Hasselblatt R, Nieminen MS, Toivonen J, Tikkanen MI, Ylikorkala O. Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmeno-pausal women. Am J Obstet Gynecol 184: 904–909, 2001.
4. Campos C, Sartorio CL, Casali KR, Fernandes RO, Llesuy S, da Rosa Araujo AS, Bello-Klein A, Rigatto KV. Low-dose estrogen is as effective as high-dose treatment in rats with postmenopausal hypertension. J Cardiovasc Pharmacol 63: 144–151, 2014.
5. Compton DR, Sheng S, Carlson KE, Rebacz NA, Lee IY, Katzenel-lenbogen BS, Katzenellenbogen JA. Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity. J Med Chem 47: 5872–5893, 2004.
6. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004. Hypertension 52: 818–827, 2008.
7. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA. Hypercholes-terolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 110: 3849–3857, 2004.
8. Dieudonne MN, Leneveu MC, Giudicelli Y, Pecquery R. Evidence for functional estrogen receptors alpha and beta in human adipose cells: regional specificities and regulation by estrogens. Am J Physiol Cell Physiol 286: C655–C661, 2004.
9. Dobrian AD, Davies MJ, Prewitt RL, Lauterio TJ. Development of hypertension in a rat model of diet-induced obesity. Hypertension 35: 1009–1015, 2000.
10. Dunne FP, Barry DG, Ferriss JB, Grealy G, Murphy D. Changes in blood pressure during the normal menstrual cycle. Clin Sci 81: 515-518, 1991.
11. Eferakeya AE, Imasuen JE. Relationship of menopause to serum cholesterol and arterial blood pressure in some Nigerian women. Public Health 100: 28-32, 1986.
12. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45: 356-362, 2005.
13. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, Group HR. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 49-57, 2002.
14. Gupte M, Boustany-Kari CM, Bharadwaj K, Police S, Thatcher S, Gong MC, English VL, Cassis LA. ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 295: R781-R788, 2008.
15. Gupte M, Thatcher SE, Boustany-Kari CM, Shoemaker R, Yian-nikouris F, Zhang X, Karounos M, Cassis LA. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler Thromb Vasc Biol 32: 1392-1399, 2012.
16. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 206: 13-22, 2003.
17. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 87: 677-682, 2000.
18. Hernandez I, Delgado JL, Diaz J, Quesada T, Teruel MJ, Llanos MC, Carbonell LF. 17fj-Estradiol prevents oxidative stress and decreases-blood pressure in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 279: R1599-R1605, 2000.
19. Ingberg E, Theodorsson A, Theodorsson E, Strom JO. Methods for long-term 17beta-estradiol administration to mice. Gen Comp Endocrinol 175: 188-193, 2012.
20. Ji H, Menini S, Zheng W, Pesce C, Wu X, Sandberg K. Role of angiotensin-converting enzyme 2 and angiotensin(1–7) in 17beta-oestra-diol regulation of renal pathology in renal wrap hypertension in rats. Exp Physiol 93: 648–657, 2008.
21. Joyner J, Neves LA, Granger JP, Alexander BT, Merrill DC, Chap-pell MC, Ferrario CM, Davis WP, Brosnihan KB. Temporal-spatial expression of ANG-(1–7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. Am J Physiol Regul Integr Comp Physiol 293: R169–R177, 2007.
22. Karpanou EA, Vyssoulis GP, Georgoudi DG, Toutouza MG, Toutou-zas PK. Ambulatory blood pressure changes in the menstrual cycle of hypertensive women. Significance of plasma renin activity values. Am J Hypertens 6: 654–659, 1993.
23. Lundholm L, Moverare S, Steffensen KR, Nilsson M, Otsuki M, Ohlsson C, Gustafsson JA, Dahlman-Wright K. Gene expression profiling identifies liver X receptor alpha as an estrogen-regulated gene in mouse adipose tissue. J Mol Endocrinol 32: 879–892, 2004.
24. Matyskova R, Zelezna B, Maixnerova J, Koutova D, Haluzik M, Maletinska L. Estradiol supplementation helps overcome central leptin resistance of ovariectomized mice on a high fat diet. Horm Metab Res 42: 182–186, 2010.
25. Morgan MA, Pfaff DW. Effects of estrogen on activity and fear-related behaviors in mice. Horm Behav 40: 472–482, 2001.
26. Nickenig G, Baumer AT, Grohe C, Kahlert S, Strehlow K, Rosenk-ranz S, Stablein A, Beckers F, Smits JF, Daemen MJ, Vetter H, Bohm M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 97: 2197–2201, 1998.
27. Ong KL, Tso AW, Lam KS, Cheung BM. Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension 51: 1142–1148, 2008.
28. Perez-Lopez FR, Chedraui P, Gilbert JJ, Perez-Roncero G. Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women’s Health Initiative era. Fertil Steril 92: 1171–1186, 2009.
29. Pripp U, Hall G, Csemiczky G, Eksborg S, Landgren BM, Schenck-Gustafsson K. A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease. J Hypertens 17: 1379–1386, 1999.
30. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, and Writing Group for the Women’s Health Initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333, 2002.
31. Schunkert H, Danser AH, Hense HW, Derkx FH, Kurzinger S, Riegger GA. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 95: 39-45, 1997.
32. Shenoy V, Grobe JL, Qi Y, Ferreira AJ, Fraga-Silva RA, Collamat G, Bruce E, Katovich MJ. 17fj-Estradiol modulates local cardiac renin-angiotensin system to prevent cardiac remodeling in the DOCA-salt model of hypertension in rats. Peptides 30: 2309-2315, 2009.
33. Siamopoulos KC, Papanikolaou S, Elisaf M, Theodorou J, Pappas H, Papanikolaou N. Ambulatory blood pressure monitoring in normotensive pregnant women. J Hum Hypertens 10, Suppl 3: S51-S54, 1996.
34. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett-Connor E, Hulley SB. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-Progestin Replacement Study (HERS). Circulation 103: 638-642, 2001.
35. Sorensen MB, Rasmussen V, Jensen G, Ottesen B. Temporal changes in clinic and ambulatory blood pressure during cyclic post-menopausal hormone replacement therapy. J Hypertens 18: 1387-1391, 2000.
36. Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens 3: 427-433, 1989.
37. Staessen JA, Ginocchio G, Thijs L, Fagard R. Conventional and ambulatory blood pressure and menopause in a prospective population study. J Hum Hypertens 11: 507-514, 1997.
38. Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA, Katzenellenbogen BS. Antagonists selective for estrogen receptor alpha. Endocrinology 143: 941-947, 2002.
39. van Beresteyn EC, van t Hof MA, De Waard H. Contributions of ovarian failure and aging to blood pressure in normotensive perimeno-pausal women: a mixed longitudinal study. Am J Epidemiol 129: 947-955, 1989.
40. Xue B, Zhang Z, Beltz TG, Guo F, Hay M, Johnson AK. Estrogen regulation of the brain renin-angiotensin system in protection against angiotensin II-induced sensitization of hypertension. Am J Physiol Heart Circ Physiol 307: H191-H198, 2014.
41. Yiannikouris F, Gupte M, Putnam K, Thatcher S, Charnigo R, Rateri DL, Daugherty A, Cassis LA. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension 60: 1524-1530, 2012.
42. Zhu L, Brown WC, Cai Q, Krust A, Chambon P, McGuinness OP, Stafford JM. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes 62: 424–434, 2013.